Genpharmasec Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	16.03	12.31	-1.69	11.25	-2.09
Depreciation & Amortization	21.68	8.12	0.42	0.2	0.14
Loss (Gain) From Sale of Assets	-	-	-	-	0.09
Loss (Gain) From Sale of Investments	0.47	-	-	-	-
Provision & Write-off of Bad Debts	6.94	3.94	4.27	1.75	-
Other Operating Activities	-25.71	-16.69	2.95	-6.1	-3.3
Change in Accounts Receivable	-153.47	-48.9	-33.91	7.39	10.77
Change in Inventory	-57.18	6.45	8.33	2.13	-22.08
Change in Accounts Payable	229.07	58.8	10.09	-48.51	-8.95
Change in Other Net Operating Assets	-213.37	5.84	-19.92	1.29	1.98
Operating Cash Flow	-175.52	29.87	-29.46	-30.6	-23.44
Capital Expenditures	-5.21	-57.05	-0.18	-0.16	-0.81
Sale of Property, Plant & Equipment	-	-	-	-	0.02
Investment in Securities	-42.15	-	-176.4	3.33	2.73
Other Investing Activities	7.69	22.83	4.73	0.23	0.66
Investing Cash Flow	132.63	-152.98	-280.63	3.63	4.18
Long-Term Debt Issued	56.95	-	54.8	30.4	-
Long-Term Debt Repaid	-7.27	-6.23	-57.64	-	-
Net Debt Issued (Repaid)	49.69	-6.23	-2.84	30.4	-
Issuance of Common Stock	-	-	484.51	-	-
Other Financing Activities	-10.48	-6.26	-3.2	0.42	-
Financing Cash Flow	39.21	-12.49	478.47	30.82	-
Miscellaneous Cash Flow Adjustments	6.91	0	-	-	-
Net Cash Flow	3.24	-135.6	168.38	3.85	-19.26
Free Cash Flow	-180.73	-27.19	-29.64	-30.76	-24.25
Free Cash Flow Margin	-12.63%	-8.06%	-9.75%	-12.05%	-8.88%
Free Cash Flow Per Share	-0.11	-0.05	-0.10	-0.11	-0.09
Cash Interest Paid	-	6.26	3.75	-	-
Cash Income Tax Paid	-	0.74	0.41	-2.55	0.3
Levered Free Cash Flow	-190.02	-9.09	-29.15	-43.65	-44.21
Unlevered Free Cash Flow	-182.26	-6.37	-26.59	-43.3	-44.21
Change in Working Capital	-194.94	22.18	-35.41	-37.69	-18.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.